Minalrestat_product_DataBase

Bioactivity	Minalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes[1].
Invitro	Minalrestat (100 μM) 减少原代培养的大鼠系细胞内山梨糖醇含量，而不影响的细胞内葡萄糖含量[3]。Minalrestat (100 μM, 48 h) 在原代培养的大鼠系膜细胞中引起 PKC-α 和 -β2 的积累[3]。 Western Blot Analysis[3] Cell Line:
In Vivo	Minalrestat (口服灌胃，10 mg/kg/天，持续 30 天) 可恢复糖尿病大鼠中降低的微血管反应性[1]。Minalrestat (口服灌胃，10 mg/kg) 可恢复糖尿病大鼠毛细血管后微静脉中减少的白细胞粘附和迁移白细胞数量[2]。 Animal Model:
Name	Minalrestat
CAS	129688-50-2
Formula	C19H11BrF2N2O4
Molar Mass	449.20
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Akamine EH, et al. Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther. 2003 Mar;304(3):1236-42. [2]. Cruz JW, et al. Minalrestat and leukocyte migration in diabetes mellitus. Diabetes Metab Res Rev. 2003 May-Jun;19(3):223-31. [3]. Kapor-Drezgic J, et al. Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. J Am Soc Nephrol. 1999 Jun;10(6):1193-203.

PeptideDB